THEMIS

A multinational, randomised, double-blind, placebo-controlled trial to evaluate the effect of ticagrelor 90mg twice daily on the incidence of cardiovascular death, myocardial infarction or stroke in patients with type 2 diabetes mellitus

Stadium
klaar
Middel
ticagrelor
Populatie
Diabetes Mellitus
Fase
III
First Patient In
15 november 2015
Last Patient In
10 mei 2016
Last Patient Last Visit
31 december 2018

National Lead

prof. dr. J.H. Cornel

Cardioloog

Studiedirecteur

dr. S.H.K. The

Cardioloog

De pagina is verlopen.